New drug combo aims to shrink lung tumors before surgery

NCT ID NCT07550920

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer that does not have certain gene mutations. Participants will receive the drug combination before surgery, then continue rilapentib alpha for a year after. The study will measure how many patients have no cancer cells left in their removed tumor tissue and track safety and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rilapentib alpha (a drug given by IV) plus single-agent chemotherapy (nab-paclitaxel or pemetrexed)
What this could lead to: If it works, this could point toward a new treatment option for people with early-stage lung cancer that lacks certain gene mutations, potentially improving outcomes before and after surgery.
What could go wrong: This is a very small, early-phase study (only 18 participants) at a single center, so results may not apply broadly. The drug combination may cause side effects or fail to improve response rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.